nmCRPC, demonstrated that APA added to androgen deprivation therapy (ADT) prolonged metastasis-free survival (MFS) by > 2 yrs (median 40.5 vs 16.2 mo; HR, 0.28; p < 0.0001) and provided a 55% reduction in the risk of symptomatic progression (HR, 0.45; 95% CI, 0.32-0.63; p < 0.0001) (Smith et al. N Engl J Med 2018). We examined whether treatment with APA, a next-generation androgen receptor inhibitor, provided the same benefit and safety profile in pts with or without prior RP and/or XRT (RP/XRT).
INTRODUCTION AND OBJECTIVES: APA, a next-generation androgen receptor inhibitor, added to androgen deprivation therapy (ADT) improved MFS by > 2 years (median 40.5 vs 16.2 mo; p < 0.0001) in high-risk pts with nmCRPC in the phase 3 SPARTAN study. In this post hoc analysis, we examined clinical outcomes in APA-treated pts whose PSA declined to < 0.2 ng/mL. METHODS: In SPARTAN, pts with nmCRPC with PSA doubling time of 10 months were randomized 2:1 to APA (240 mg QD) þ ADT or placebo (PBO) þ ADT. MFS, time to metastasis (mets) (TTM), and location of mets were evaluated as a function of PSA status (PSA decline to < 0.2 ng/mL at any time during the study, vs PSA not declining to < 0.2 ng/mL). Cox proportional hazard analysis estimated HRs and 95% CI.
RESULTS: Following treatment with APA, PSA declined to < 0.2 ng/mL in 319/806 (40%) pts; 1 PBO pt had a decline in PSA to < 0.2 ng/mL. APA pts with a PSA decline to < 0.2 ng/mL had a 76% risk reduction for MFS (Figure) and TTM. Compared with pts who received PBO, the APA pts with PSA that declined to < 0.2 ng/mL had an 88% risk reduction for MFS and TTM. When mets developed, depth of PSA decline (to < 0.2 ng/mL vs not reaching < 0.2 ng/mL) was not associated with location of mets (bone: 53% vs 58%; nodes: 27% vs 31%).
CONCLUSIONS: In nmCRPC pts treated with APA, a PSA decline to < 0.2 ng/mL occurred in 40% of pts, and was associated with an improvement in clinical end points, including MFS. Depth of PSA decline was not associated with a specific metastatic pattern. INTRODUCTION AND OBJECTIVES: During templated transrectal ultrasound prostate biopsy (TRUS PBx), the closer the actual PBx samples match a desired template (resulting in uniform spatial distribution of samples including regions where PCa is likely) the higher the probability of sampling PCa and avoiding a false negative. A mental model for templated PBx is a set of 12 circles (2D representation of spheres construed as the recommended centers for the cylindrical biopsy cores) evenly distributed on a posterior-anterior view of the prostate. We set out to quantify the baseline (first attempt at sampling a 12-core set) prevalence and magnitude of deviation from Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e503
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